Blar i Institutt for klinisk og molekylær medisin på tidsskrift "The Lancet Oncology"
Viser treff 1-1 av 1
-
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial
(Journal article; Peer reviewed, 2021)High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial